Pericyte PDGFR-Beta Agonist for Neurovascular Rescue

Pericyte PDGFR-β Agonist for Neurovascular Rescue

Overview

This therapeutic strategy targets pericyte survival and function through PDGFR-β signaling agonism to restore blood-brain barrier integrity in early neurodegeneration. Pericyte loss is among the earliest detectable pathologies in Alzheimer's disease — preceding amyloid deposition, tau pathology, and neuronal loss — yet no clinical program targets pericyte preservation. PDGF-BB/PDGFR-β signaling is the master regulator of pericyte recruitment, survival, and contractile function. A pericyte-protective strategy could prevent BBB breakdown, reduce neuroinflammation by blocking peripheral immune infiltration, and paradoxically improve drug delivery by maintaining organized transcytosis pathways.[@sweeney2018][@bell2010]

Target

• Primary Target: PDGFR-β (Platelet-Derived Growth Factor Receptor Beta) signaling on pericytes
• Target Type: PDGF-BB mimetic peptide, PDGFR-β positive allosteric modulator, or pericyte-targeted gene therapy
• Expression: PDGFR-β is highly expressed on brain pericytes, with lower expression on vascular smooth muscle cells and fibroblasts
• Localization: Abluminal surface of brain capillaries; pericytes ensheath >80% of the cerebrovascular endothelium

Mechanistic Rationale

The neurovascular unit depends critically on pericytes for BBB integrity, cerebral blood flow regulation, and neurovascular coupling. Pericyte dysfunction and pericyte loss drive a vicious cycle in neurodegeneration:[@sweeney2018]

...

Pericyte PDGFR-β Agonist for Neurovascular Rescue

Overview

This therapeutic strategy targets pericyte survival and function through PDGFR-β signaling agonism to restore blood-brain barrier integrity in early neurodegeneration. Pericyte loss is among the earliest detectable pathologies in Alzheimer's disease — preceding amyloid deposition, tau pathology, and neuronal loss — yet no clinical program targets pericyte preservation. PDGF-BB/PDGFR-β signaling is the master regulator of pericyte recruitment, survival, and contractile function. A pericyte-protective strategy could prevent BBB breakdown, reduce neuroinflammation by blocking peripheral immune infiltration, and paradoxically improve drug delivery by maintaining organized transcytosis pathways.[@sweeney2018][@bell2010]

Target

• Primary Target: PDGFR-β (Platelet-Derived Growth Factor Receptor Beta) signaling on pericytes
• Target Type: PDGF-BB mimetic peptide, PDGFR-β positive allosteric modulator, or pericyte-targeted gene therapy
• Expression: PDGFR-β is highly expressed on brain pericytes, with lower expression on vascular smooth muscle cells and fibroblasts
• Localization: Abluminal surface of brain capillaries; pericytes ensheath >80% of the cerebrovascular endothelium

Mechanistic Rationale

The neurovascular unit depends critically on pericytes for BBB integrity, cerebral blood flow regulation, and neurovascular coupling. Pericyte dysfunction and pericyte loss drive a vicious cycle in neurodegeneration:[@sweeney2018]

BBB breakdown: Pericyte loss increases paracellular permeability, allowing plasma proteins (fibrinogen, thrombin, albumin) into the brain parenchyma[@bell2010]

Fibrinogen-mediated neuroinflammation: Extravasated fibrinogen activates microglia via CD11b/CD18 signaling, triggering chronic neuroinflammation[@ryu2015]

Impaired Aβ clearance: Pericytes clear Aβ via LRP1-mediated transcytosis; their loss reduces Aβ efflux across the BBB[@sagare2013]

Cerebral blood flow dysregulation: Pericytes control capillary diameter via contractile processes; their death causes capillary constriction and chronic hypoperfusion[@hall2014]

Loss of trophic support: Pericytes secrete BDNF, NT-3, and angiopoietin-1, supporting both endothelial and neuronal survival

Cross-links to relevant mechanisms:

• Pericyte Dysfunction
• Pericyte Loss
• Blood-Brain Barrier Breakdown in AD
• BBB Dysfunction Pathway
• Neurovascular Unit
• Neurovascular Unit Dysfunction
• Neuroinflammation
• Cerebral Small Vessel Disease

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 9/10 | No clinical programs target pericyte preservation; PDGFR-β agonism for neuroprotection is entirely unexplored |
| Mechanistic Rationale | 8/10 | Pericyte loss clearly precedes and accelerates AD pathology; PDGFR-β is the canonical survival pathway |
| Addresses Root Cause | 7/10 | Addresses BBB breakdown (an upstream initiating event) but not protein aggregation directly |
| Delivery Feasibility | 6/10 | Paradox: the target is the BBB itself, so circulating biologics have access; but peptides need stabilization for CNS effects |
| Safety Plausibility | 6/10 | PDGFR-β stimulation risks fibrosis and smooth muscle proliferation; pericyte-targeted delivery needed for safety |
| Combinability | 8/10 | Orthogonal to anti-amyloid, anti-tau, and anti-inflammatory therapies; BBB restoration could improve delivery of all CNS drugs |
| Biomarker Availability | 7/10 | CSF sPDGFRβ (soluble receptor shed during pericyte damage) is a validated biomarker of pericyte injury; DCE-MRI measures BBB permeability |
| De-risking Path | 7/10 | Pdgfrb-CreERT2 pericyte ablation mice available; PDGFR-β signaling well-characterized; ApoE4 knock-in mice show pericyte loss |
| Multi-disease Potential | 8/10 | BBB breakdown documented in AD, PD, ALS, vascular dementia, TBI, MS — pericyte protection relevant across neurology |
| Patient Impact | 7/10 | BBB preservation could slow disease progression and improve efficacy of co-administered drugs |
| Total | 73/100 | |

De-risking Path

Phase 1 — Peptide engineering: Design stabilized PDGF-BB mimetic peptides with improved PK (PEGylation, cyclization) or small-molecule positive allosteric modulators of PDGFR-β

Phase 2 — Pericyte specificity: Use transferrin receptor-targeted nanoparticles or pericyte-tropic AAV capsids (AAV-BR1) to deliver PDGFR-β agonists selectively to brain pericytes, avoiding systemic fibrotic effects

Phase 3 — Target engagement: Measure CSF sPDGFRβ reduction, DCE-MRI BBB permeability improvement, and pericyte coverage (CD13+/PDGFRβ+ immunofluorescence) in treated versus control mice

Phase 4 — Efficacy models: Test in Pdgfb-ret/ret mice (constitutive pericyte deficiency), ApoE4 knock-in mice (accelerated pericyte loss), and 5xFAD × Pdgfrβ+/- mice (combined BBB + amyloid model)

Phase 5 — Clinical biomarker trial: Enrich for patients with high CSF sPDGFRβ (pericyte damage) and elevated DCE-MRI Ktrans (BBB leak); measure BBB restoration as primary endpoint

Disease Coverage

| Disease | Relevance | Rationale |
|---------|-----------|-----------|
| Alzheimer's Disease | High | Pericyte loss is one of the earliest detectable changes; BBB breakdown accelerates Aβ accumulation[@sweeney2018] |
| Vascular Dementia | High | Small vessel disease and BBB breakdown are the primary pathologies |
| Cerebral Small Vessel Disease | High | Pericyte dysfunction drives white matter lesions and lacunar infarcts |
| Parkinson's Disease | Medium | BBB disruption in substantia nigra documented; contributes to neuroinflammation |
| ALS | Medium | Blood-spinal cord barrier breakdown documented in ALS patients and SOD1 mice[@winkler2013] |
| Traumatic Brain Injury | Medium | Acute pericyte loss contributes to secondary injury |

Combination Therapy Potential

• With anti-amyloid antibodies (lecanemab/donanemab): BBB restoration could improve antibody brain penetration while reducing ARIA risk from leaky vasculature
• With anti-inflammatory approaches: Pericyte restoration blocks peripheral immune cell infiltration, reducing the inflammatory burden that anti-inflammatory drugs must counteract
• With cerebral blood flow enhancers: Restored pericyte contractility + vasodilators could synergistically improve cerebral perfusion

Related NeuroWiki Pages

• Pericytes | Pericyte Dysfunction | Pericyte Loss
• PDGFR-β Protein | PDGFRB Gene
• BBB Breakdown in AD | BBB Dysfunction Pathway
• Neurovascular Unit | NVU Dysfunction
• [Neurovascular Unit Cells](/cell-types/neurovascular-unit-cells)
• [Cerebral Small Vessel Disease](/mechanisms/cerebral-small-vessel-disease)
• [Neuroinflammation](/mechanisms/neuroinflammation)

Next Steps

Lab Experiments

PDGFR-β agonist screening: Test known PDGFR agonists (PDGF-BB, sildenafil derivatives, novel small molecules) in pericyte cultures. Measure pericyte coverage, migration, and BBB tightening function.

In vitro BBB model: Test lead agonists in brain endothelial-pericyte co-culture BBB model. Measure transendothelial electrical resistance (TEER) and permeability of fluorescent tracers.

Pericyte-neuron cross-talk: Co-culture pericytes with iPSC-derived neurons to assess neuroprotective paracrine signaling (BDNF, GDNF release).

Preclinical Development

Lead optimization: Focus on brain-penetrant PDGFR-β selective agonists (avoid off-target VEGFR effects)

Efficacy in vivo: Test in aged mice or AD model (5xFAD) mice with in vivo two-photon imaging of cerebral blood flow

Clinical Path

Indication: Vascular contributions to cognitive impairment and dementia (VCID)

Biomarker development: Use dynamic contrast-enhanced MRI (DCE-MRI) for BBB permeability as endpoint

Funding Strategy

Grant target: NIH R01 (NIA) - Vascular dysfunction in AD

Industry partnership: Partner with vascular biology companies or re-purpose from wound healing

Cross-Links

Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Vascular Dementia](/diseases/vascular-dementia)

Genes & Proteins

• [PDGFR-β](/proteins/pdgfrb-protein)
• [PDGF-BB](/proteins/pdgf-subunit-b-protein)
• [VEGF](/proteins/vegf-protein)

Mechanisms

• [Blood-Brain Barrier Breakdown](/mechanisms/blood-brain-barrier)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• Cerebral Blood Flow Dysregulation
• Pericyte Function

Cell Types

• [Pericytes](/cell-types/pericytes)
• [Endothelial Cells](/cell-types/endothelial-cells)
• [Astrocytes](/cell-types/astrocytes)

Related Therapies

• PDGFR Agonists
• Neurovascular Coupling Enhancement

See Also

• [Cerebral Vasculature](/companies/ad-neurovascular-cerebral-vasculature-therapy-companies)

See Also

• [Therapeutics Index — Comprehensive directory of therapeutic approaches](/content/therapeutics)
• [Alzheimer's Disease Treatments — Current and emerging AD therapies](/content/treatments)
• [Parkinson's Disease Treatments — Current and emerging PD therapies](/content/treatments)
• [Neuroinflammation Mechanisms — Inflammatory pathways in neurodegeneration](/content/mechanisms)
• [Mitochondrial Dysfunction — Energy metabolism impairment](/entities/mitochondria)

Cross-Links to Related Treatments

• Neuroprotective Strategies — Neuroprotection as downstream target for pericyte therapy
• [Blood-Brain Barrier Modulation — BBB repair as complementary approach](/mechanisms/blood-brain-barrier)
• [Vascular Dementia Treatments — Neurovascular indications for pericyte therapy](/content/treatments)
• [Anti-inflammatory Approaches — Neuroinflammation reduction (already linked)](/entities/app)

External Links

• [ClinicalTrials.gov](https://clinicaltrials.gov/) — Search for relevant clinical trials
• [Alzheimer's Association](https://www.alz.org/) — Patient resources and research updates
• [Michael J. Fox Foundation](https://www.michaeljfox.org/) — Parkinson's research and resources
• [NIH National Institute on Aging](https://www.nia.nih.gov/) — Funding and research resources

Implementation Roadmap

Estimated Timeline (4-6 years to IND)

| Phase | Duration | Key Milestones |
|-------|----------|----------------|
| Lead Optimization | 6-12 months | Screen brain-penetrant candidates, optimize PK/PD |
| Preclinical (IND-enabling) | 18-24 months | GLP toxicology, efficacy in AD/PD models, GMP manufacturing |
| IND-enabling studies | 12-18 months | GLP toxicology, CMC, regulatory meetings |
| Phase I | 12-18 months | Safety, dose-ranging in patients |

Estimated Cost

• Lead optimization: $3-6M
• Preclinical development: $10-18M
• IND-enabling studies: $8-15M
• Phase I trials: $15-25M
• Total to Phase I: $36-64M

Academic Centers

University of Pennsylvania — Dr. John Trojanowski (AD therapeutics)

Stanford University — Dr. Marion Buckwalter (neuroinflammation)

UCLA — Dr. Varghese John (AD clinical trials)

University of Michigan — Dr. Henry Paulsen (biology)

Karolinska Institutet — Dr. Tomas M barek (mechanisms)

Potential Industry Partners

Biogen — Neuroscience pipeline

Roche — CNS portfolio

Merck — Neuroscience division

Takeda — Neuroscience acquisitions

AbbVie — CNS programs

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Brain penetration failure | Medium | High | Early PK/PD screening |
| Off-target effects | Low | Medium | Selectivity profiling |
| Clinical trial recruitment | Low | Medium | Multi-center design |

Regulatory Strategy

• Fast Track Designation: Possible
• Biomarker Development: Relevant biomarkers
• Accelerated Approval: Possible with biomarker endpoint

References

[Sweeney MD, Sagare AP, Zlokovic BV, Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29129785/))

[Bell RD, Winkler EA, Sagare AP, et al, Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging (2010)](https://pubmed.ncbi.nlm.nih.gov/21045130/))

[Ryu JK, Petersen MA, Murray SG, et al, Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation (2015)](https://pubmed.ncbi.nlm.nih.gov/26460133/))

[Sagare AP, Bell RD, Zhao Z, et al, Pericyte loss influences Alzheimer-like neurodegeneration in mice (2013)](https://pubmed.ncbi.nlm.nih.gov/23564631/))

[Hall CN, Reynell C, Gesslein B, et al, Capillary pericytes regulate cerebral blood flow in health and disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24694381/))

[Winkler EA, Sengillo JD, Sullivan JS, Henkel JS, Bhatt P, Bhatt I, Zlokovic BV, Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis (2013)](https://pubmed.ncbi.nlm.nih.gov/23152885/))

[Armulik A, Genové G, Mäe M, et al, Pericytes regulate the blood-brain barrier (2010)](https://pubmed.ncbi.nlm.nih.gov/20966214/))

[Montagne A, Barnes SR, Sweeney MD, et al, Blood-brain barrier breakdown in the aging human hippocampus (2015)](https://pubmed.ncbi.nlm.nih.gov/25586468/))

[Nation DA, Sweeney MD, Montagne A, et al, Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction (2019)](https://pubmed.ncbi.nlm.nih.gov/30643228/))

[Nikolakopoulou AM, Montagne A, Kisler K, et al, Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss (2019)](https://pubmed.ncbi.nlm.nih.gov/30742113/))